4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Stan V. Smith, Ph.D. made an individual purchase of 100,000 shares of MAIA's common stock, and warrants to purchase 100,000 shares, of MAIA's common stock for an aggregate purchase price of $225,900 as part of the Company's recent private placement of common stock and warrants announced by the Company on October 28, 2024, and which closed on November 1, 2024. "As one of our original investors, Stan has participated in nearly every private placement financing round since our Company's inception. We

Late breaking abstract to provide new updates from THIO-101 Phase 2 clinical trial in non-small cell lung cancer (NSCLC) Poster to highlight long-term therapeutic benefits of THIO sequenced with cemiplimab beyond treatment cessation MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that a late-breaking abstract (LBA) detailing new updates from its Phase 2 THIO-101 clinical trial was selected for oral and poster presentation at the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held November 6-10, 2024, in Houston, Texas. The updates will

MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,079,784 shares of common stock at a purchase price of $2.259 per share, in a private placement to accredited investors and certain Company directors. Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $2.51 per share, which price represents the greater of the book or market value of the stock on the date the definitive agreements were executed (subject t

MAIA seeks to advance two new THIO-derived telomere-targeting molecules to clinical trials MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract related to the company's second generation of proprietary telomere-targeting THIO prodrugs has been accepted for poster presentation during the upcoming 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place October 23-25, 2024, in Barcelona, Spain. The Symposium is hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI)

16 patients surpassed 12-month survival follow-up THIO's substantial survival benefit in third line surpasses comparable standard-of-care overall survival of 5.8 months Median survival follow-up in third line was 10.6 months Treatment with THIO followed by Libtayo® has been generally well-tolerated to date MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announces favorable interim survival benefit from its lead clinical candidate THIO, a telomere-targeting treatment for patients with advanced non-small cell lung cancer (NSCLC). A Phase 2 clinical trial, THIO-101, is evalu

Updates from THIO-101 to include response rates and survival follow-up MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that Chairman and Chief Executive Officer Vlad Vitoc, M.D. will present at the H.C. Wainwright & Co. 26th Annual Global Investment Conference taking place September 9–11, 2024, in New York City. Dr. Vitoc's presentation will reveal the latest clinical data from MAIA's Phase 2 THIO-101 clinical trial of lead candidate THIO sequenced with the immune checkpoint inhibitor cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC

THIO followed by cemiplimab shown to be well tolerated throughout trial, with far lower toxicity compared to standard of care treatments 6 patients on trial regimen for more than 12 months have completed up to 21 cycles, with treatment ongoing MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announces positive treatment updates from its Phase 2 clinical trial, THIO-101, evaluating THIO sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who failed two or more standard-of-care therapy regimen

FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage company developing telomere-targeting immunotherapies for cancer, today announced the validation of clinical and regulatory pathways for viable therapies leveraging the cell's telomeric functions as evidenced by the U.S. Food and Drug Administration (FDA) approval of imetelstat, a treatment for low- to intermediate-risk hematologic malignancies (myelodysplastic syndromes) from Geron Corporation. "MAIA is one of the earliest pioneers of telomere targeting as a therapeutic strategy, and we share in the ent

New science for cancer therapy drives powerful value proposition Exceptional measures of efficacy by lead drug THIO in Phase 2 clinical trial Funding of more than $12M year-to-date, including $7.4 million in Q2'24 so far Secured continued insider investment through independent board members' participation in private placement equity financings Newest data shows THIO's strong outperformance against standard-of-care treatments in non-small cell lung cancer (NSCLC) 38% overall response rate (ORR) in third-line (3L) setting (THIO 180mg) vs. ~6% for currently available treatments in a similar population 5.5 months median progression-free survival (PFS) (3L, THIO 180mg) more th

THIO's favorable disease control and overall response rates exceed reported standard-of-care data in third line treatment MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced new efficacy data from its Phase 2 THIO-101 clinical trial evaluating THIO sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who failed 2 or more standard-of-care therapy regimens. Updated results show a favorable overall response rate (ORR) of 38% and a disease control rate (DCR) of 85% from THIO + CPI in third-line

SC 13D/A - MAIA Biotechnology, Inc. (0001878313) (Subject)

SC 13D - MAIA Biotechnology, Inc. (0001878313) (Subject)

SC 13D - MAIA Biotechnology, Inc. (0001878313) (Subject)

SC 13G - MAIA Biotechnology, Inc. (0001878313) (Subject)

SC 13G - MAIA Biotechnology, Inc. (0001878313) (Subject)

SC 13G - MAIA Biotechnology, Inc. (0001878313) (Subject)